Economic evaluation and budgetary burden of mepolizumab in severe refractory eosinophilic asthma
Objective: Mepolizumab is indicated as an additional treatment of severe refractory eosinophilic asthma. The observed differences in population subgroups according to plasma eosinophil count, the existence of patients with high levels of immunoglobulin E who are candidates of omalizumab and mepoliz...
সংরক্ষণ করুন:
| প্রকাশিত: | Farmacia Hospitalaria |
|---|---|
| প্রধান লেখক: | , , , , |
| বিন্যাস: | Artigo |
| ভাষা: | Inglês |
| প্রকাশিত: |
Sociedad Española de Farmacia Hospitalaria
2019
|
| বিষয়গুলি: | |
| অনলাইন ব্যবহার করুন: | https://www.redalyc.org/articulo.oa?id=365963307005 https://www.redalyc.org/journal/3659/365963307005/ https://www.redalyc.org/journal/3659/365963307005/html/ https://www.redalyc.org/journal/3659/365963307005/365963307005.epub https://www.redalyc.org/journal/3659/365963307005/movil |
| ট্যাগগুলো: |
কোনো ট্যাগ নেই, প্রথমজন হিসাবে ট্যাগ করুন!
|